Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1998, for Bioanalytical Systems, Inc. (Note: The input metadata lists "Inotiv, Inc.", but the filing text explicitly identifies the registrant as Bioanalytical Systems, Inc.). The Company manufactures scientific instruments for trace organic compound determination and provides laboratory services. The reporting period includes the impact of an Initial Public Offering (IPO) completed in November 1997 and the acquisition of Vetronics, Inc. in October 1997.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1998 | Six Months Ended Mar 31, 1998 | Balance Sheet (Mar 31, 1998) |
|---|---|---|---|
| Total Revenue | $4.45 million | $8.78 million | - |
| Net Income | $0.23 million | $0.43 million | - |
| Gross Margin | 57.3% | 57.3% | - |
| Operating Income | $0.33 million | $0.65 million | - |
| Cash & Equivalents | - | - | $2.99 million |
| Long-Term Debt | - | - | $0.06 million |
| Current Ratio | - | - | 4.0x |
| Diluted EPS | $0.05 | $0.10 | - |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 22.0% for the quarter and 22.6% for the six-month period compared to the prior year. This was driven by a 39% increase in services revenue and a 14% increase in product revenue, the latter aided by the Vetronics acquisition.
- Profitability: Despite revenue growth, Net Income decreased 12.8% for the quarter ($231k vs $265k) and 5.7% for the six-month period ($427k vs $453k). This decline was due to a 33% increase in Operating Expenses.
- Expense Increases:
- R&D: Increased 74.9% (quarter) and 52.1% (six months) due to accelerated product development and NIH/NASA grant projects.
- G&A: Increased 45.8% (quarter) and 52.0% (six months) due to higher property taxes from new facilities and legal costs defending a patent infringement suit.
- Liquidity: Cash and cash equivalents surged from $161,000 (Sept 30, 1997) to $2.99 million (Mar 31, 1998), primarily due to $9.36 million in net proceeds from the November 1997 IPO.
- Debt Reduction: The Company used IPO proceeds to repay approximately $6.6 million in indebtedness, reducing long-term debt significantly.
Outlook, Risks, and Unusual Items
- Capital Expenditures: The Company anticipates increased capital expenditures in fiscal 1998 and 1999 for facility renovations and laboratory equipment. A subsequent event noted a commitment to purchase three mass spectrometers for approximately $770,000.
- Legal Proceedings: The Company is defending a patent infringement suit filed by CMA Microdialysis Holding A.B. regarding microdialysis probes. Management believes the outcome will not have a material adverse effect, though legal expenses may impact current earnings.
- Forward-Looking Statements: The filing includes standard disclaimers regarding strategic plans, future profitability, and capital requirements, noting that actual results may differ due to risks and uncertainties.
- Board Changes: Two directors, Thomas A. Hiatt and William C. Mulligan, resigned from the Board of Directors on May 7, 1998, with no stated disagreements regarding company operations.
Investor Verification Checklist
- Expense Sustainability: Verify if the sharp increases in R&D and G&A expenses are one-time costs related to the IPO and facility expansion or indicative of a new, higher cost structure.
- Legal Exposure: Monitor the status of the CMA Microdialysis patent infringement suit and associated legal costs.
- Capital Allocation: Confirm the utilization of the remaining IPO proceeds ($2.8 million) and the execution of planned capital expenditures for facility expansion.
- Debt Covenants: Review the terms of the new $7.5 million line of credit established in March 1998 and ensure compliance with covenants.
- Acquisition Integration: Assess the performance of the newly acquired Vetronics, Inc. products in driving future product revenue growth.